EIKON THERAPEUTICS INC
EIKNNASDAQTrading Snapshot
- Day Range
- $10.26 – $10.43
- 52-Week Range
- $7.90 – $17.40
- Volume
- $4.85B
- Avg Volume
- $5.79B
- Shares Outstanding
- 54.1M
- Next Earnings
- Sep 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $130M
- Last Q Revenue
- $32M
- P/E Ratio
- -3.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.00
- Dividend Yield
- 0.00%
Why Investors Own EIKN
- ✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EIKON THERAPEUTICS INC
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial
Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consumer staples up 2%, tech down 1.9%. Durable goods orders rise 0.3%.
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and SPT.
Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer
"Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved outcomes to patients with
Eikon Therapeutics: Behind The Rough Debut
Eikon Therapeutics focuses on the development of solid tumor therapies. Read more on recent trials for this California-based biotech.
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC)Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumorsInitial data from a Phase 1/2 study of EIK1003 in combin